Screener
Immix Biopharma, Inc. IMMX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | 2026 / For the Three Months Ended / March 31, | 2025 / For the Three Months Ended / March 31, |
|---|---|---|
| Purchase of property and equipment | (32,486) | (67,713) |
| Proceeds from the sale of short-term investments | 3,000,000 | - |
| Purchase of short-term investments | (7,768,350) | - |
| Net cash used in investing activities | (4,800,836) | (67,713) |
| Financing Activities: | ||
| Proceeds from exercise of stock options | 33,532 | - |
| Payments of deferred offering costs | (71,093) | - |
| Net cash provided by financing activities | (37,561) | - |
Document
FAQ
- What is Immix Biopharma, Inc.'s investing cash flow?
- Immix Biopharma, Inc. (IMMX) reported investing cash flow of -$4.8M in Q1 2026.
- How has Immix Biopharma, Inc.'s investing cash flow changed year-over-year?
- Immix Biopharma, Inc.'s investing cash flow decreased by 6990.0% year-over-year, from -$67.71K to -$4.8M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Immix Biopharma, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude